These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

346 related items for PubMed ID: 7608286

  • 21. Bone mass and body composition of adult women with congenital virilizing 21-hydroxylase deficiency after glucocorticoid treatment since infancy.
    Hagenfeldt K, Martin Ritzén E, Ringertz H, Helleday J, Carlström K.
    Eur J Endocrinol; 2000 Nov; 143(5):667-71. PubMed ID: 11078991
    [Abstract] [Full Text] [Related]

  • 22. Bone mineral status, bone turnover markers and vitamin D status in children with congenital adrenal hyperplasia.
    Okten A, Cakir M, Makuloglu M.
    Minerva Endocrinol; 2012 Sep; 37(3):275-82. PubMed ID: 22766894
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Fractures and bone mineral density in adult women with 21-hydroxylase deficiency.
    Falhammar H, Filipsson H, Holmdahl G, Janson PO, Nordenskjöld A, Hagenfeldt K, Thorén M.
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4643-9. PubMed ID: 17878254
    [Abstract] [Full Text] [Related]

  • 25. Bone mineral density and body composition before and during treatment with gonadotropin-releasing hormone agonist in children with central precocious and early puberty.
    Boot AM, De Muinck Keizer-Schrama S, Pols HA, Krenning EP, Drop SL.
    J Clin Endocrinol Metab; 1998 Feb; 83(2):370-3. PubMed ID: 9467543
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: alterations in cortisol pharmacokinetics at puberty.
    Charmandari E, Hindmarsh PC, Johnston A, Brook CG.
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2701-8. PubMed ID: 11397874
    [Abstract] [Full Text] [Related]

  • 28. Real-world impact of glucocorticoid replacement therapy on bone mineral density: retrospective experience of a large single-center CAH cohort spanning 24 years.
    Iervolino LL, Ferraz-de-Souza B, Martin RM, Costa FC, Miranda MC, Mendonça BB, Bachega TS.
    Osteoporos Int; 2020 May; 31(5):905-912. PubMed ID: 31897546
    [Abstract] [Full Text] [Related]

  • 29. Cortical bone mineral density in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
    El-Maouche D, Collier S, Prasad M, Reynolds JC, Merke DP.
    Clin Endocrinol (Oxf); 2015 Mar; 82(3):330-7. PubMed ID: 24862755
    [Abstract] [Full Text] [Related]

  • 30. Impact of total cumulative glucocorticoid dose on bone mineral density in patients with 21-hydroxylase deficiency.
    Chakhtoura Z, Bachelot A, Samara-Boustani D, Ruiz JC, Donadille B, Dulon J, Christin-Maître S, Bouvattier C, Raux-Demay MC, Bouchard P, Carel JC, Leger J, Kuttenn F, Polak M, Touraine P, Centre des Maladies Endocriniennes Rares de la Croissance and Association Surrénales.
    Eur J Endocrinol; 2008 Jun; 158(6):879-87. PubMed ID: 18390993
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Growth hormone therapy alone or in combination with gonadotropin-releasing hormone analog therapy to improve the height deficit in children with congenital adrenal hyperplasia.
    Quintos JB, Vogiatzi MG, Harbison MD, New MI.
    J Clin Endocrinol Metab; 2001 Apr; 86(4):1511-7. PubMed ID: 11297576
    [Abstract] [Full Text] [Related]

  • 33. Bone mineral density and bone turnover in Romanian children and young adults with classical 21-hydroxylase deficiency are influenced by glucocorticoid replacement therapy.
    Zimmermann A, Sido PG, Schulze E, Al Khzouz C, Lazea C, Coldea C, Weber MM.
    Clin Endocrinol (Oxf); 2009 Oct; 71(4):477-84. PubMed ID: 19170706
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Normal bone health in young adults with 21-hydroxylase enzyme deficiency undergoing glucocorticoid replacement therapy.
    Borges JH, de Oliveira DM, de Lemos-Marini SHV, Geloneze B, Guerra-Júnior G, Gonçalves EM.
    Osteoporos Int; 2022 Jan; 33(1):283-291. PubMed ID: 34406442
    [Abstract] [Full Text] [Related]

  • 36. Adiponectin levels are high in children with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency.
    Völkl TM, Simm D, Körner A, Kiess W, Kratzsch J, Dörr HG.
    Acta Paediatr; 2009 May; 98(5):885-91. PubMed ID: 19236311
    [Abstract] [Full Text] [Related]

  • 37. Improvement in bone mineral density and body composition in survivors of childhood acute lymphoblastic leukemia: a 1-year prospective study.
    Marinovic D, Dorgeret S, Lescoeur B, Alberti C, Noel M, Czernichow P, Sebag G, Vilmer E, Léger J.
    Pediatrics; 2005 Jul; 116(1):e102-8. PubMed ID: 15995009
    [Abstract] [Full Text] [Related]

  • 38. BclI polymorphism of the glucocorticoid receptor gene is associated with increased bone resorption in patients on glucocorticoid replacement therapy.
    Koetz KR, van Rossum EF, Ventz M, Diederich S, Quinkler M.
    Clin Endocrinol (Oxf); 2013 Jun; 78(6):831-7. PubMed ID: 23134110
    [Abstract] [Full Text] [Related]

  • 39. Reduction in daily hydrocortisone dose improves bone health in primary adrenal insufficiency.
    Schulz J, Frey KR, Cooper MS, Zopf K, Ventz M, Diederich S, Quinkler M.
    Eur J Endocrinol; 2016 Apr; 174(4):531-8. PubMed ID: 26811406
    [Abstract] [Full Text] [Related]

  • 40. Bone mineral density in relation to glucocorticoid substitution therapy in adult patients with 21-hydroxylase deficiency.
    Jääskeläinen J, Voutilainen R.
    Clin Endocrinol (Oxf); 1996 Dec; 45(6):707-13. PubMed ID: 9039336
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.